Eckert & Ziegler Awards Travel Grants to Young Scientists in Nuclear Medicine

Berlin, March 3, 2014. The Eckert & Ziegler Abstract Award is entering its seventh year. Young scientists can enter the competition with their innovative scientific research in the field of nuclear medicine. The deadline for submission is April 28, 2014. Each year, the Eckert & Ziegler Abstract Award supports young scientists and PhD students who would like to present their findings to a wider audience at the annual congress of the European Association of Nuclear Medicine (EANM) in October 2014. Five travel grants of € 1,000 each will be awarded by Eckert & Ziegler, one of the leading manufacturers of isotope products in Europe, and the European Association of Nuclear Medicine (EANM). The jury consists of a panel of independent, unbiased EANM experts. The five winners will receive their awards on October 22, 2014 at the EANM Annual Congress in Gothenburg, Sweden.

Not only are the awards entering their seventh year, they are also gaining increasing popularity in the industry. Last year, almost 600 young scientists from all over the world entered the competition in the hope of winning the coveted award.

“Nuclear medicine has huge potential as it can be used to diagnose diseases non-invasively, which would be impossible or very difficult to detect with other methods. It helps patients in terms of early diagnosis and in deciding on a targeted therapy. This is why we hope to help ensure with these awards that the substantial progress in medical imaging can soon be transformed into more precise, faster or less expensive methods of diagnosis and therapy,” commented Karolin Riehle, spokeswoman for Eckert & Ziegler AG.

Eligibility for Participation
All EANM members who are not older than 38 years of age at the time of submission are eligible to participate. Applications can be submitted electronically at eanm14.eanm.org. The submission deadline is April 28, 2014.

Eckert & Ziegler
The Eckert & Ziegler Group (ISIN DE0005659700), with approximately 700 employees, is one of the world’s largest providers of isotope component technology for radiation therapy and nuclear medicine. Eckert & Ziegler supports the widespread use of PET/CT hybrid systems by expanding its production sites for radioactive contrast agents and by developing automated synthesis modules in which scientists can produce new diagnostic substances with the requisite pharmaceutical quality.

For further information, please contact:
Eckert & Ziegler AG, Karolin Riehle, Public Relations
Robert-Rössle-Str. 10, D-13125 Berlin, Tel.: +49 (0) 30 / 941084-138, Fax -112
Email: karolin.riehle@dont-want-spam.ezag.de, www.ezag.com